Members of the Latin American Association for the Study of the Liver (ALEH) are invited to an exclusive networking gathering at The Park @ TLM during this year's The Liver Meeting (TLM). Connect with fellow ALEH members and society leadership, strengthen professional relationships, and engage in conversations about topics and opportunities relevant to the Latin American liver community. We look forward to welcoming you to this special networking event.

Calling all current Liver Fellow Network content creators and alumni! Join us on Saturday, November 7, from 9:45 - 10:45 AM at Meet Up Summit 5 & 6 for an exclusive gathering to catch up with familiar faces and meet this year's new content creators and LFN leads.

Attention all current Emerging Liver Scholars and alumni! Join us on Friday, November 6, from 1 - 2 PM at Meet-Up Summit 6 for an exclusive gathering to network and build meaningful connections across the ELS community. Whether you're looking to catch up with familiar faces or meet this year's awardees, we'd love to see you there!

Calling all current AASLD Foundation Emerging Liver APPs and alumni! Join us on Friday, November 6, from 2 - 3 PM at Meet Up Summit 5 for an exclusive gathering to network and build meaningful connections with fellow awardees!

Join AASLD's Diversity, Equity, and Inclusion (DE&I) Committees for a networking Meet-Up at The Park @ TLM during The Liver Meeting (TLM). Connect with colleagues from across the liver community, expand your professional network, and engage in meaningful conversations about advancing diversity, equity, inclusion, and belonging in hepatology. All attendees interested in fostering a more inclusive community are welcome.

Start your #TLM26 experience by connecting with local hepatology leaders who are excited to meet you, share insights, and help make your first meeting a success. Bring your questions, and leave with new connections and confidence for the week ahead.

Noncirrhotic portal hypertension has historically been described using heterogeneous and region-specific terminology—such as idiopathic portal hypertension (IPH), noncirrhotic portal fibrosis (NCPF), obliterative portal venopathy, and nodular regenerative hyperplasia—leading to substantial variability in diagnosis, reporting, and international research collaboration.

Disseminate the Harmonization efforts that have resulted in key statements that will inform clinical practice and clinical trial design.

Alcohol-associated hepatitis (AH) carries one of the highest short-term mortality rates in hepatology, yet the therapeutic armamentarium has changed little in four decades. In response, the National Institute on Alcohol Abuse and Alcoholism (NIAAA) consolidated its alcohol-associated hepatitis consortia into the Alcohol-Associated Hepatitis Network (AlcHepNet), a coordinated multi-center translational and clinical network designed to accelerate biomarker development, generate natural-history data, and test integrated treatment strategies for AH and alcohol use disorder (AUD).

This Community Conversations session brings AASLD attendees into direct dialogue with AlcHepNet leadership. Three fifteen-minute presentations will review the published evidence the network has generated to date, describe the ongoing ITAALD integrated-therapy trial, and outline concrete opportunities for the broader hepatology community — investigators, clinicians, trainees, advocacy partners, and patients — to engage with, contribute to, and benefit from AlcHepNet. A moderated audience Q&A will close the hour.

Liver fibrosis is a key determinant of liver-related morbidity and mortality across a broad spectrum of chronic liver diseases, including MASLD/MASH, viral hepatitis, and alcohol-related liver disease. Recent years have witnessed remarkable progress in non-invasive assessment tools, including serum biomarkers, imaging technologies, artificial intelligence–assisted risk stratification, and multi-omics approaches, which are transforming the screening, diagnosis and monitoring of liver fibrosis. At the same time, emerging anti-fibrotic therapies and disease-modifying treatments are creating new opportunities for preventing fibrosis progression and improving patient outcomes.

This interactive session will bring together international experts from AASLD and CHESS to discuss the latest advances in non-invasive fibrosis assessment, emerging therapeutic strategies, and challenges in translating scientific discoveries into clinical practice. The discussion will highlight current evidence, unmet clinical needs, and future directions for precision medicine in liver fibrosis.